Direct NAD+ precursor studied for mitochondrial biogenesis, metabolic health, cardiovascular function, and longevity mechanisms. More bioavailable than NR for some tissues per recent comparative studies.
15–20 minutes in plasma; rapidly converted to NAD+ in tissues
SKUs
2
Evidence
Moderate Evidence
NMN (nicotinamide mononucleotide) is another NAD+ precursor, one step closer in the synthesis pathway to NAD+ than NR. It has been studied in animals and in a growing number of human trials for its ability to raise NAD+ levels and improve metabolic markers. Interest in NMN was significantly boosted by work from David Sinclair's lab at Harvard showing dramatic effects in aged mice.
NAD+ Precursor Research
Multiple human trials have confirmed that oral NMN raises blood NAD+ levels. A Japanese trial (Keio University) in healthy men showed 250mg/day NMN was safe and raised blood NAD+ metabolites. Larger trials from multiple institutions are ongoing.
Metabolic Health and Aging
Animal studies from the Sinclair lab and others showed dramatic improvements in muscle function, energy, and longevity markers in aged mice given NMN. A human trial at Washington University found that NMN improved muscle insulin sensitivity and physical performance in postmenopausal women with prediabetes.
Exercise Performance Research
A small Japanese trial found that recreational runners who took NMN for six weeks improved their oxygen utilization during exercise compared to placebo. This was an early signal that muscle energy metabolism may be enhanced, though replication is needed.
Oral NMN raises blood NAD+ metabolites in human trials.
Animal studies show significant metabolic and longevity improvements in aged rodent models.
Human trial in postmenopausal women showed improved muscle insulin sensitivity.
Small exercise trial showed improvements in aerobic capacity.
Safety profile appears favorable in completed short-term human trials.
Human trial data are still relatively limited in scale and duration. The dramatic animal results have not yet been replicated in large human trials. Some debate exists about whether NMN or NR raises NAD+ more efficiently, as some research suggests NMN may be converted to NR before entering cells. The FDA issued a guidance in 2022 that NMN cannot be sold as a dietary supplement because it is under investigation as a new drug — though enforcement has been inconsistent.
NMN is one step further along the NAD+ synthesis pathway than NR. Your cells convert NMN into NAD+ through a single enzymatic step, making it a direct and efficient precursor. Research suggests that NMN may enter cells through a specific transporter protein (Slc12a8) that delivers it directly into the cytoplasm. Once inside, it is converted to NAD+ and supports all the same cellular processes — energy production in mitochondria, DNA repair via PARP enzymes, and sirtuin-mediated gene regulation. The close relationship between NMN and NR means that for practical purposes, they raise NAD+ through closely related paths, and ongoing research is examining whether one is more effective than the other.
NMN appears safe in completed short-term human trials with no significant adverse effects reported. It is widely sold as a supplement despite the FDA's 2022 guidance that it does not qualify as a dietary supplement. Long-term safety in humans has not been established. The Japanese safety trial confirmed no adverse clinical or laboratory effects at 250mg/day over 12 weeks in healthy men.
Moderate Evidence
This compound has been studied in Phase 1 or Phase 2 human trials. Evidence is encouraging but more large-scale trials are needed.
Published Research Ranges
250–1000mg/day oral in human trials; 125–500mg/day in Japanese safety/efficacy studies
Research Context Only: These are ranges reported in published scientific studies for educational reference. They are not dosing recommendations. This is not medical advice. Always consult a qualified healthcare professional.
Sources listed here are from the platform research library. All links open the original publication. No citations are generated by AI.
Nicotinamide Mononucleotide Increases Muscle Insulin Sensitivity in Prediabetic Women
A research agenda for ageing in China in the 21st century (2nd edition): Focusing on basic and translational research, long-term care, policy and social networks
Research Education Only: This profile is for educational purposes only. All information is sourced from published scientific literature. This is not medical advice. Not for human consumption. Consult qualified medical professionals for any health decisions.
We use cookies to enhance your research experience and analyze platform usage. By continuing, you agree to our Cookie Policy.